ERBB2 and gastroesophageal junction adenocarcinoma: All HER2-targeted agents (including antibodies, small molecular tyrosine kinase inhibitors and antibody drug conjugates) developed to date (Fig. 2) were developed for amplification and protein overexpression of the HER2 wild-type genes in breast and gastric/ GEJ adenocarcinoma.